Peripartum cardiomyopathyMANAGEMENT

OBSTETRIC PRESENTATIONS · 12 SECTIONS

⚲

526 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Chorioamnionitis Eclampsia Ectopic Pregnancy (Ruptured)Ectopic Pregnancy (Unruptured)HELLP Syndrome Hyperemesis gravidarum Peripartum cardiomyopathy Placenta previa Placental abruption Postpartum Endometritis Postpartum hemorrhage Postpartum infection Preeclampsia Preeclampsia-eclampsia Preterm labor Sepsis in pregnancy Septic abortion Shoulder dystocia Spontaneous Abortion (Incomplete)Spontaneous Abortion (Missed)Spontaneous Abortion (Threatened)Threatened-inevitable-incomplete abortion Umbilical cord prolapse

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp73

First look and triggers

›High risk presentations

›Cardiogenic shock

›SBP < 90 mmHg

›MAP < 65 mmHg

›Cool extremities with altered mentation

›Acute pulmonary edema

›SpO2 < 90% on room air

›Bibasilar crackles with orthopnea

›Malignant arrhythmia

›Sustained ventricular tachycardia

›New atrial fibrillation with rapid ventricular response

›Peripartum collapse

›Sudden collapse during labor or delivery raises amniotic fluid embolism concern

›Sudden collapse with chest pain raises SCAD concern

›Thromboembolic event

›New focal neurologic deficit

›New unilateral leg swelling

Why this diagnosis is missed

›Symptom overlap with normal pregnancy and postpartum state

›Dyspnea attributed to gravid uterus and normal physiologic changes

›Peripheral edema attributed to normal fluid retention

›Fatigue attributed to sleep deprivation and normal postpartum recovery

›Orthopnea and exertional dyspnea often dismissed as late pregnancy discomfort

›Consequence of delayed recognition

›Presentation in overt pulmonary edema or cardiogenic shock rather than early heart failure

›Diagnosis of exclusion requires active exclusion of mimics rather than a single positive test

Iatrogenic harm from routine ED and obstetric interventions

›Intubation

›Positive pressure ventilation reduces preload and increases right ventricular afterload

›Precipitates decompensation in low ejection fraction

›Induction hypotension risk with standard dose propofol

›Reduced dose etomidate or ketamine preferred for hemodynamic stability

›Sedation

›Myocardial depressant agents worsen forward flow

›Benzodiazepine accumulation risk in a low output state

›Fluid loading

›Empiric crystalloid bolus for hypotension or tachycardia precipitates flash pulmonary edema

›Unlike sepsis, hypotension here usually reflects pump failure rather than volume depletion

›Oxygen

›Correct hypoxemia without targeting supranormal saturations

›Antepartum oxygenation target maintained for fetal oxygen delivery

›Vasopressors

›Phenylephrine for spinal induced hypotension increases afterload

›Can precipitate cardiogenic shock in unrecognized disease

›Norepinephrine preferred if a vasopressor is required in cardiogenic shock

›Mechanical circulatory support

›Intra-aortic balloon pump limited by gravid uterine aortic compression antepartum

›Postpartum placement more feasible

›Percutaneous ventricular assist device or veno-arterial ECMO preferred for refractory antepartum shock

›Anticoagulation

›Hypercoagulable state of pregnancy and low ejection fraction both increase thrombosis risk

›Anticoagulation held or bridged around delivery for bleeding risk

›Fibrinolysis

›Relatively contraindicated near term and postpartum for hemorrhage risk

›Reserved for massive pulmonary embolism or stroke with no safer alternative

›Analgesia

›NSAIDs worsen fluid retention and renal function

›Antepartum NSAID use also carries ductus arteriosus constriction risk

›Opioids used cautiously for hypotension risk

Team activation and consults

›Escalation and consultation triggers

›Cardiology

›New heart failure in pregnancy or postpartum

›Cardiogenic shock or inotrope requirement

›Obstetrics and maternal fetal medicine

›Antepartum presentation

›Delivery timing and mode decision

›Anesthesia

›Anticipated operative delivery

›Neuraxial anesthesia planning

›Critical care

›Refractory shock or hypoxemia

›Mechanical circulatory support evaluation

›Advanced heart failure or transplant service

›Refractory cardiogenic shock

›Profoundly reduced LVEF

02History/hx42

Presenting symptoms and why they are missed

›Heart failure symptoms

›Dyspnea on exertion

›Orthopnea

›Paroxysmal nocturnal dyspnea

›Peripheral edema

›Fatigue disproportionate to activity

›Persistent dry cough

›Overlap with expected pregnancy and postpartum symptoms

›Mild dyspnea and edema common in normal late pregnancy

›Symptom progression or symptoms at rest distinguish pathologic pattern

›Associated symptoms

›Palpitations

›Chest discomfort

›Abdominal fullness from hepatic congestion

Timing and onset window

›Classic timing

›Onset final month of pregnancy through 5 months postpartum

›Broadened definitions capture cases earlier in pregnancy or later postpartum

›Delivery context

›Symptom onset timed relative to delivery date

›Prior pregnancy history of similar symptoms

Risk factors and exposures

›Demographic and obstetric risk

›Multiparity

›Multifetal gestation

›Advanced maternal age above 30 years

›Adolescent pregnancy

03Physical Exam/exam26

Vitals and appearance

›Vital sign pattern

›Resting tachycardia

›Tachypnea

›SpO2 reduction on room air

›Blood pressure normal, elevated, or low depending on severity

›General appearance

›Diaphoresis

›Inability to lie flat

Cardiopulmonary and volume findings

›Cardiac findings

›Displaced or diffuse point of maximal impulse

›S3 gallop

›New mitral or tricuspid regurgitant murmur

›Pulmonary findings

›Bibasilar crackles

›Diminished breath sounds from effusion

›Volume findings

›Elevated jugular venous pressure

›Hepatojugular reflux

›Peripheral edema

›Bilateral and pitting typical

›Asymmetric edema raises DVT concern

›Hepatomegaly

PITFALLS

›Exam limitations

›Mild bilateral edema present in normal pregnancy

›Resting tachycardia present in normal late pregnancy

04Differential Diagnosis/ddx33

Life threats to exclude

›Pulmonary embolism

›Acute PE ICD-10 I26

›D-dimer physiologically elevated in pregnancy, limits rule out value

›Preeclampsia with pulmonary edema

›Concurrent hypertension and proteinuria

›Preeclampsia ICD-10 O14

›Amniotic fluid embolism

›Sudden collapse during labor or immediately postpartum

›Amniotic fluid embolism ICD-10 O88.1

›Disseminated intravascular coagulopathy frequently accompanies

›Myocardial infarction

›Type 1 MI ICD-10 I21

›Spontaneous coronary artery dissection concern

›Higher incidence in the peripartum period

›Consider with chest pain, ischemic ECG changes, and few traditional risk factors

›Pre-existing cardiomyopathy unmasked by pregnancy

›Dilated cardiomyopathy ICD-10 I42.0

›Hypertrophic cardiomyopathy ICD-10 I42.1

›Pregnancy hemodynamic load exposes previously compensated disease

Other mimics

›Pulmonary causes

›Pneumonia ICD-10 J18.9

›Asthma exacerbation ICD-10 J45.901

›Anemia

›ICD-10 D64.9

›Thyrotoxicosis

›ICD-10 E05.90

05Laboratory Tests/lt36

Core labs

›Baseline panel

›Electrolytes

›Sodium

›Potassium

›Renal function

›Creatinine

›Complete blood count

›Anemia contributor

›Platelet count for preeclampsia or HELLP overlap

›Liver enzymes

›Congestive hepatopathy pattern

›Preeclampsia screen

›Urine protein to creatinine ratio

›Uric acid

Cardiac biomarkers

›Natriuretic peptides

›BNP or NT-proBNP elevation supports heart failure

›Mild elevation occurs in normal pregnancy

›Marked elevation favors pathologic heart failure over normal physiology

›Trend supports treatment response

›Troponin

›Ischemia evaluation

›Dynamic rise or fall with ischemic ECG changes supports ACS or SCAD

›Mild elevation possible from catecholamine surge of labor without ACS

›Investigational marker

›16 kDa prolactin fragment proposed pathogenic mediator, not a bedside test

06Diagnostic Tests/dt46

Scoring Systems

›Risk stratification

›No validated formal risk score specific to peripartum cardiomyopathy

›IPAC registry derived risk factors

›LVEF below 30% at diagnosis associated with lower recovery likelihood

›More dilated left ventricular end diastolic diameter associated with lower recovery likelihood

›Use as prognostic context, not a decision rule

MRI

›Cardiac MRI role

›Myocarditis overlap evaluation

›Tissue characterization

›Late gadolinium enhancement pattern

›Safety in pregnancy

›Noncontrast preferred antepartum

›Gadolinium avoided when feasible antepartum

›Acute ED limitations

›Not first line in the unstable patient

›CT indications

›CT pulmonary angiography for PE concern

›Hypoxia not explained by pulmonary edema alone

›Radiation counseling

›Maternal benefit prioritized when clinically indicated

›Fetal shielding when feasible

Ultrasound

›Echocardiography

›Primary diagnostic test

›LVEF below 45%

07Disposition/dispo22

Level of care selection

›ICU criteria

›Cardiogenic shock

›Vasopressor or inotrope requirement

›Mechanical ventilation

›Refractory arrhythmia

›Stepdown or telemetry criteria

›IV diuresis with hemodynamic stability

›New oral GDMT initiation requiring monitoring

›Ward criteria

›Hemodynamically stable

›Responding to oral or IV diuretic therapy

Obstetric-cardiology joint disposition

›Antepartum admission

›Maternal instability

›Fetal status concerns

›Delivery planning trigger

›Maternal deterioration despite therapy prompts delivery discussion regardless of gestational age

›Postpartum disposition

›Continued inpatient GDMT optimization

Transfer criteria

›Higher level of care needs

›Mechanical circulatory support evaluation

›Advanced heart failure or transplant evaluation

›Tertiary maternal fetal medicine or neonatal care antepartum

08Treatment/t160

Antepartum pharmacotherapy

›ACE inhibitors, ARBs, and ARNI avoided

›Enalapril PO, typical non-pregnancy starting dose 2.5 to 5 mg twice daily

›Contraindicated antepartum, fetal renal dysgenesis and oligohydramnios risk

›Sacubitril-valsartan PO, typical non-pregnancy starting dose 24/26 mg twice daily

›Contraindicated antepartum for the same fetal renal risk

›Mineralocorticoid receptor antagonist avoided

›Spironolactone PO, typical non-pregnancy starting dose 12.5 to 25 mg daily

›Contraindicated antepartum, antiandrogenic fetal effect

›SGLT2 inhibitor avoided

›Dapagliflozin PO, typical non-pregnancy dose 10 mg daily

›Contraindicated antepartum, insufficient human safety data

›Warfarin avoided

›Warfarin PO 5 mg daily initial, titrated to INR target 2.0 to 3.0

›Relatively contraindicated antepartum, especially first trimester

›Fetal warfarin syndrome risk

›Non-dihydropyridine calcium channel blockers avoided

›Diltiazem extended release PO 120 to 360 mg daily, typical non-HF dosing

›Avoided throughout, negative inotropy worsens systolic heart failure

›Beta blockers

›Metoprolol succinate PO 12.5 to 25 mg daily initial

›Titrate every 2 weeks as tolerated

›Target up to 200 mg PO daily

›Carvedilol PO 3.125 mg twice daily initial

›Titrate by doubling every 2 weeks as tolerated

›Target 25 mg twice daily, up to 50 mg twice daily if body weight above 85 kg

›Atenolol avoided

›Associated with fetal growth restriction

›Afterload reduction substitute for ACE inhibitor

›Hydralazine PO 10 to 25 mg three to four times daily initial

›Titrate to maximum 300 mg per day

›Hydralazine IV for acute severe hypertension

›5 to 10 mg IV every 20 minutes

›Maximum per local protocol, reassess for reflex tachycardia

›Isosorbide dinitrate PO 10 to 20 mg three times daily initial

›Titrate to maximum 40 mg three times daily

›Combination used as an ACE inhibitor substitute for afterload reduction in pregnancy

›Loop diuretic

›Furosemide IV or PO 20 to 40 mg initial

›Titrate to urine output and congestion response

›Avoid overdiuresis, reduces uteroplacental perfusion

›Digoxin

›Digoxin PO 0.125 to 0.25 mg daily

›Target level 0.5 to 0.9 ng/mL

›Safe in pregnancy at therapeutic levels

Postpartum pharmacotherapy and GDMT

›ACE inhibitor compatible with breastfeeding

›Enalapril PO 2.5 to 5 mg twice daily initial

›Titrate to target 10 to 20 mg twice daily

›Captopril PO 6.25 to 12.5 mg three times daily initial

›Titrate to target 50 mg three times daily

›Preferred for very early postpartum initiation given short half life

›Beta blocker continuation

›Continue carvedilol or metoprolol succinate at antepartum doses or up-titrate

›Compatible with breastfeeding

›Mineralocorticoid receptor antagonist

›Spironolactone PO 12.5 to 25 mg daily initial

›Titrate to target 50 mg daily

›Limited breastfeeding safety data, generally considered low risk at these doses

›ARNI as alternative to ACE inhibitor

›Sacubitril-valsartan PO 24/26 mg twice daily initial

›Titrate to target 97/103 mg twice daily

›Avoid during breastfeeding, insufficient safety data

›SGLT2 inhibitor

›Dapagliflozin PO 10 mg daily

›Avoid during breastfeeding, insufficient safety data

›Loop diuretic continuation

›Furosemide as needed for congestion

›Compatible with breastfeeding

Bromocriptine adjunct therapy

›Rationale

›Dopamine agonist suppresses prolactin

›Reduces generation of the pathogenic cleaved 16 kDa prolactin fragment implicated in disease mechanism

›Evidence base

›Small pilot and multicenter European trials suggest possible LVEF recovery benefit

›Evidence is not definitive and not universally adopted in guidelines

›Dosing

›Bromocriptine PO, short course for milder presentation

›2.5 mg once daily for 1 week

›Bromocriptine PO, extended course for LVEF 25% or lower or cardiogenic shock

›2.5 mg twice daily for 2 weeks

›Then 2.5 mg once daily for 6 weeks

›Anticoagulation caveat

›Bromocriptine itself carries thrombotic risk

›Mandatory concurrent prophylactic or therapeutic anticoagulation while on bromocriptine

›Lactation suppression

›Discuss infant feeding plan before initiation

Anticoagulation for thromboembolic risk

›Risk threshold

›LVEF 35% or lower supports prophylactic anticoagulation

›Intracardiac thrombus or very low LVEF supports therapeutic anticoagulation instead

›Antepartum agent

›Enoxaparin SC, does not cross the placenta

›Prophylactic 40 mg SC daily

›Therapeutic 1 mg/kg SC every 12 hours

›Warfarin and direct oral anticoagulants avoided in pregnancy

›Postpartum agent

›Enoxaparin or warfarin

›Warfarin PO 5 mg daily initial, titrated to INR target 2.0 to 3.0

›Compatible with breastfeeding

›Direct oral anticoagulants generally avoided during breastfeeding

›Insufficient infant safety data

›Peridelivery management

›Hold or bridge anticoagulation around delivery for bleeding risk

›Neuraxial anesthesia timing depends on last anticoagulant dose

Arrhythmia, sudden death risk, and device therapy

›Risk factors for malignant arrhythmia

›LVEF 25% or lower

›QRS prolongation

›Family history of cardiomyopathy or arrhythmia

›Consider genetic evaluation, titin gene variants implicated in some cases

›Wearable cardioverter-defibrillator

›Bridges the high risk period pending recovery reassessment

›Permanent ICD decision deferred 3 to 6 months given meaningful recovery potential

›Continuous rhythm monitoring while worn

›Permanent ICD

›Considered if LVEF remains 35% or lower at reassessment despite optimized GDMT

›Unstable tachyarrhythmia

›Synchronized cardioversion

›Amiodarone IV for AF or ventricular arrhythmia

›150 mg IV over 10 minutes, may repeat once

›Infusion 1 mg per minute for 6 hours

›Then 0.5 mg per minute for 18 hours

›Generally avoided for chronic use during breastfeeding

›High iodine content transfers to milk

Mechanical circulatory support, transplant, and refractory therapy

›Escalation trigger, therapy not working

›Persistent hypoperfusion despite diuresis and afterload reduction

›Rising lactate or worsening renal function on inotrope support

›Inotrope bridge before mechanical support

›Dobutamine IV infusion

›Start 2.5 mcg/kg/min

›Titrate 2.5 mcg/kg/min every 15 to 30 minutes

›Typical range 2.5 to 20 mcg/kg/min

›Continuous ECG and blood pressure monitoring during titration

›Milrinone IV infusion

›Start 0.125 mcg/kg/min, loading dose avoided in hypotension

›Titrate to 0.25 to 0.5 mcg/kg/min

›Renal dose adjustment required

›Hypotension risk from vasodilation

›Temporary mechanical support

›Intra-aortic balloon pump

›Limited antepartum by gravid uterine aortic compression

›Percutaneous ventricular assist device

›Veno-arterial ECMO

›Bridge in refractory cardiogenic shock

›Durable support and transplant

›Durable LVAD as bridge to recovery or transplant

›Heart transplant for persistent severe dysfunction without recovery

›Higher allosensitization from prior pregnancy increases rejection risk

Delivery timing and mode

›Joint obstetric-cardiology decision

›Maternal hemodynamic stability primary determinant of timing

›Gestational age and fetal status weighed against maternal risk

›Preferred approach when stable

›Vaginal delivery preferred

›Assisted second stage reduces Valsalva related afterload swings

›Cesarean reserved for obstetric indication or maternal instability requiring expedited delivery

›Anesthesia planning

›Neuraxial anesthesia preferred

›Blunts hemodynamic swings of labor

›General anesthesia avoided when possible

›Myocardial depressant effect of induction agents

›Monitoring during labor and delivery

›Continuous ECG and pulse oximetry

›Arterial line for severe dysfunction

›Strict intake and output

09Special Populations/sp24

Pregnancy

›Diagnostic definition

›New LV systolic dysfunction, LVEF below 45%

›Onset final month of pregnancy through 5 months postpartum

›Diagnosis of exclusion after directed workup

›Future pregnancy counseling

›Recurrence and decompensation risk

›Substantially higher if LVEF has not normalized before conceiving again

›Reported recurrence or decompensation rates roughly 20 to 50 percent in a subsequent pregnancy

›Preconception evaluation

›Repeat echocardiography before considering future pregnancy

›Discourage future pregnancy if LVEF remains below 50 to 55 percent

›Contraception counseling

›Discuss reliable contraception given recurrence risk

Geriatric

›Advanced maternal age considerations

›Advanced maternal age above 30 years is itself a risk factor

›Higher comorbidity burden

›Chronic hypertension more common

›Preexisting cardiac disease more common

Pediatrics

›Not a pediatric diagnosis

›Applies to the pregnant or postpartum patient, not the neonate

›Fetal and neonatal considerations

›Maternal medication safety informs fetal exposure risk

›Preterm delivery planning if early delivery required for maternal instability

›Neonatology involvement

10Background/b26

Epidemiology

›Incidence

›Roughly 1 in 1,000 to 1 in 4,000 live births in the United States

›Substantially higher incidence reported in Nigeria and Haiti

›Mortality

›In-hospital mortality roughly 2 to 5 percent in contemporary high-resource cohorts

›Higher mortality reported in lower-resource settings

›Recovery

›Approximately 50 percent of patients recover LVEF to 50 percent or higher within 6 months

›Recovery can continue up to 12 to 24 months in some patients

Pathophysiology

›Proposed mechanism

›Antiangiogenic and oxidative stress state of late pregnancy

›Cleavage of prolactin into an antiangiogenic 16 kDa fragment

›STAT3 pathway dysregulation implicated in preclinical models

›Vascular and myocardial injury

›Antiangiogenic fragment impairs cardiac microvasculature

›Genetic contribution

›Titin truncating variants identified in a subset of cases

›Overlap with genetic dilated cardiomyopathy susceptibility

Therapeutic Considerations

›Treatment goals

›Guideline directed heart failure therapy adapted to pregnancy stage

›Early recognition to avoid presentation in shock

›Support LV recovery while minimizing fetal and infant medication exposure

›Harm avoidance

›Contraindicated antepartum agents carry teratogenic and fetal renal risk

›Empiric fluid loading worsens pump failure

11Patient Discharge Instructions/pdi23

Copy discharge instructions

›Home plan

›Daily weights

›Same time each morning

›Fluid and salt plan

›Follow clinician target for daily fluid intake

›Avoid added salt

›Medication plan

›Take heart failure medications exactly as prescribed

›Do not stop medications without clinician advice

›Follow up

›Cardiology and obstetric or postpartum follow up within 7 days

›Repeat echocardiogram as scheduled

›Return now or call emergency services

›Trouble breathing at rest

›Chest pain

›Fainting or near fainting

›Weight gain 2 kg or more in 2 days

›Swelling rapidly worsening

›Palpitations with dizziness

Future pregnancy counseling for the chart

›Counseling points

›Discuss recurrence risk before attempting future pregnancy

›Recommend cardiology evaluation and repeat echocardiogram before conceiving again

›Discuss reliable contraception until cardiac function reassessed

12References/r15

Clinical guidelines and consensus

›Heart failure and cardio-obstetric guidance

›AHA scientific statement on peripartum cardiomyopathy

›Diagnostic criteria and management framework

›ESC position statement on peripartum cardiomyopathy

›LVEF threshold and classic timing definition

›ESC guideline on cardiovascular disease in pregnancy

›Medication safety in pregnancy and breastfeeding

Evidence based sources

›Bromocriptine evidence

›German pilot study of bromocriptine in peripartum cardiomyopathy

›Suggested improved LVEF recovery in a small cohort

›Multicenter trial comparing short versus extended bromocriptine course

›No definitive superiority of the extended course established

›Registry data

›IPAC registry

›LVEF and LV size at diagnosis associated with recovery likelihood

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed September 13, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.